"Development of a Single-Tube, Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions"
Roughly 7% of non-small cell lung carcinomas (NSCLC) harbor oncogenic fusions involving ALK, ROS1, and RET. While tumors harboring ALK fusions are highly sensitive to crizotinib, emerging preclinical and clinical data have demonstrated that patients with ROS1 or RET fusions may also benefit from inhibitors targeting these two kinases. Utilizing a transcript-based method, a combination of 3' over-expression and fusion-specific detection strategies to detect ALK, ROS1 and RET fusion transcripts in NSCLC tumors was designed. Assay validation, implemented on the nCounter® Analysis System, was performed with 295 NSCLC specimens and shows that the assay is highly sensitive and specific.
During the webinar, a brief introduction to nCounter® Technology will be followed by a detailed description of efforts to develop and validate the multiplexed assay for ALK, ROS1, and RET.
- Understand the importance of fusions involving ALK, ROS1, and RET genes in lung cancer
- Case study on the development and validation of a multiplexed assay to detect ALK, ROS1, and RET fusions
- Comparisons of the multiplexed assay to IHC and FISH
- Basic introduction to nCounter Technology
Download the Webinar